• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.82% Nasdaq Up0.62%

    Acorda Therapeutics, Inc. (ACOR)

    27.35 Down 0.24(0.87%) 12:37PM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Acorda Therapeutics, Inc.
    420 Saw Mill River Road
    Ardsley, NY 10502
    United States - Map
    Phone: 914-347-4300
    Fax: 914-347-4560
    Website: http://www.acorda.com

    Index Membership:N/A
    Full Time Employees:535

    Business Summary 

    Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that is in the Phase IIb clinical trial for the treatment of OFF periods in Parkinson’s disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; and Ampyra/Dalfampridine that is in the Phase I pharmacokinetic studies for the treatment of chronic post-stroke deficits. Further, it develops Plumiaz, a proprietary nasal spray formulation of diazepam to treat people with epilepsy; Cimaglermin alfa/Neuregulins that has completed a Phase I clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase I clinical trial for the treatment of MS; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; and Brigham and Women’s Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Acorda Therapeutics, Inc.

    Corporate Governance 
    Acorda Therapeutics, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 2.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Ron Cohen M.D., 60
    Founder, Chief Exec. Officer, Pres and Director
    Mr. Michael W. Rogers B.A., M.B.A., 56
    Chief Financial Officer
    Ms. Jane Wasman J.D., 60
    Gen. Counsel, Corp. Sec. and Pres of International
    Ms. Lauren M. Sabella , 55
    Chief Commercial Officer
    Dr. Enrique J. Carrazana M.D. , 54
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders